Monday, September 21, 2026 | UTC
About | Contact | API Status
Sign In Subscribe
Live
AAPL $336.13 -0.26%
MSFT $493.78 -0.80%
GOOGL $349.54 +0.64%
AMZN $253.71 +1.00%
TSLA $364.27 -0.53%
META $665.75 -2.43%
NVDA $222.27 +1.34%
JPM $349.67 +0.10%
BTC $35.91 +6.18%
ETH $25.18 +7.79%
Latest Signing ceremony for contribution agreements between WHO and France Oct 17, 2024
AAPL
$336.13
▼ 0.26%
MSFT
$493.78
▼ 0.80%
GOOGL
$349.54
▲ 0.64%
AMZN
$253.71
▲ 1.00%
TSLA
$364.27
▼ 0.53%
META
$665.75
▼ 2.43%
NVDA
$222.27
▲ 1.34%
JPM
$349.67
▲ 0.10%

Top Stories

Markets →
Science Daily
An international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and cardiovascular complications in people with chronic kidney disease who do not have diabetes. The results could open the door to a much-needed new treatment option for the majority of CKD patients who have long had limited choices.
science  Jul 16, 2026

Stay ahead of the markets.

Get free access to breaking news, stock data, and market analysis.

Subscribe Free